Ketamine metabolite. Decreases intracellular D-serine (a NMDA co-agonist) concentrations in PC-12 cells (IC50 = 0.18 nM). Exerts antidepressant effects in mice.
Sold under license from the NIH, US patent 62/313,309
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 276.16. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.62 mL||18.11 mL||36.21 mL|
|5 mM||0.72 mL||3.62 mL||7.24 mL|
|10 mM||0.36 mL||1.81 mL||3.62 mL|
|50 mM||0.07 mL||0.36 mL||0.72 mL|
References are publications that support the products' biological activity.
Singh et al (2016) Ketamine metabolites enantioselectively decrease intracellular D-serine concentrations in PC-12 cells. PLoS One 11 e0149499 PMID: 27096720
Zanos et al (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 481 PMID: 27144355
If you know of a relevant reference for 2S,6S-Hydroxynorketamine hydrochloride, please let us know.
View Related Products by Target
Keywords: 2S,6S-Hydroxynorketamine hydrochloride, supplier, Potent, AMPA, agonists, agonism, ketamine, metabolites, antidepressants, ketamine, enantiomer, 2S,6S-HNK, AMPA, Receptors, NMDA, Receptors, Ketamine, and, Metabolites, Ketamine, and, Metabolites, Tocris Bioscience
Citations for 2S,6S-Hydroxynorketamine hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for 2S,6S-Hydroxynorketamine hydrochloride. Do you know of a great paper that uses 2S,6S-Hydroxynorketamine hydrochloride from Tocris? If so please let us know.
2S,6S-Hydroxynorketamine hydrochloride Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.